RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.

New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.

Add to Collection
2019 Jun 17 Others Fist_Author_Year_PM

Full Author : ['Kaul, Upendra', 'Parmar, Deven', 'Manjunath, K', 'Shah, Mitesh', 'Parmar, Krupi', 'Patil, Kishor P', 'Jaiswal, Ashok']
Journal Title : Cardiovascular diabetology
Chapter : Section3
Journal Year : 2019
Cited by : Not Available

BACKGROUND: Saroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an improvement in lipid and glycemic parameters through the PPAR-alpha and gamma agonist actions, respectively. It was granted .....

Keywords : ["new dual peroxisome proliferator activate receptor agonistsaroglitazar", "nonalcoholic fatty liver disease integrate analysis", "real world evidence", "diabetic dyslipidemia"]